Cargando…

Admission Glucose and In-hospital Mortality after Acute Myocardial Infarction in Patients with or without Diabetes: A Cross-sectional Study

BACKGROUND: Hyperglycemia on admission has been found to elevate risk for mortality and adverse clinical events after acute myocardial infarction (AMI), but there are evidences that the relationship of blood glucose and mortality may differ between diabetic and nondiabetic patients. Prior studies in...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Shi, Murugiah, Karthik, Li, Na, Li, Xi, Xu, Zi-Hui, Li, Jing, Cheng, Chen, Mao, Hong, Downing, Nicholas S, Krumholz, Harlan M, Jiang, Li-Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5381309/
https://www.ncbi.nlm.nih.gov/pubmed/28345539
http://dx.doi.org/10.4103/0366-6999.202733
Descripción
Sumario:BACKGROUND: Hyperglycemia on admission has been found to elevate risk for mortality and adverse clinical events after acute myocardial infarction (AMI), but there are evidences that the relationship of blood glucose and mortality may differ between diabetic and nondiabetic patients. Prior studies in China have provided mixed results and are limited by statistical power. Here, we used data from a large, nationally representative sample of patients hospitalized with AMI in China in 2001, 2006, and 2011 to assess if admission glucose is of prognostic value in China and if this relationship differs depending on the presence or absence of diabetes. METHODS: Using a nationally representative sample of patients with AMI in China in 2001, 2006, and 2011, we categorized patients according to their glucose levels at admission (< 3.9, 3.9–7.7, 7.8–11.0, and ≥11.1 mmol/L) and compared in-hospital mortality across these admission glucose categories, stratified by diabetes status. Among diabetic and nondiabetic patients, separately, we employed logistic regression to assess the differences in outcomes across admission glucose levels while adjusting for the same covariates. RESULTS: Compared to patients with euglycemia (5.8%), patients with moderate hyperglycemia (13.1%, odds ratio [OR] = 2.44, 95% confidence interval [CI, 2.08–2.86]), severe hyperglycemia (21.5%, OR = 4.42, 95% CI [3.78–5.18]), and hypoglycemia (13.8%, OR = 2.59, 95% CI [1.68–4.00]), all had higher crude in-hospital mortality after AMI regardless of the presence of recognized diabetes mellitus. After adjustment for patients’ characteristics and clinical status, however, the relationship between admission glucose and in-hospital mortality was different for diabetic and nondiabetic patients (P for interaction = 0.045). Among diabetic patients, hypoglycemia (OR = 3.02, 95% CI [1.20–7.63]), moderate hyperglycemia (OR = 1.75, 95% CI [1.04–2.92]), and severe hyperglycemia (OR = 2.97, 95% CI [1.87–4.71]) remained associated with elevated risk for mortality, but among nondiabetic patients, only patients with moderate hyperglycemia (OR = 2.34, 95% CI [1.93–2.84]) and severe hyperglycemia (OR = 3.92, 95% CI [3.04–5.04]) were at elevated mortality risk and not hypoglycemia (OR = 1.12, 95% CI [0.60–2.08]). This relationship was consistent across different study years (P for interaction = 0.900). CONCLUSIONS: The relationship between admission glucose and in-hospital mortality differs for diabetic and nondiabetic patients. Hypoglycemia was a bad prognostic marker among diabetic patients alone. The study results could be used to guide risk assessment among AMI patients using admission glucose. TRIAL REGISTRATION: www.clinicaltrials.gov, NCT01624883; https://clinicaltrials.gov/ct2/show/NCT01624883